The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials (Q26829564)

main subject

phase II clinical trial

0 references

0 references

5 references

25 April 2019

17 September 2019

19 September 2019

2 October 2019

7 November 2019

heterocyclic compound

1 reference

biomedical investigative technique

17 September 2019

1 reference

19 September 2019

1 reference

2 October 2019

1 reference

7 November 2019

1 reference

7 November 2019

1 reference

7 November 2019

1 reference

1 reference

8 December 2020

2

Jes Olesen

0 references

Peer Carsten Tfelt-Hansen

series ordinal

1

object named as

Peer C. Tfelt-Hansen

1 reference

language of work or name

1 reference

June 2012

1 reference

The journal of headache and pain : official journal of the Italian Society for the Study of Headaches

1 June 2012

7 references

25 April 2019

17 September 2019

19 September 2019

2 October 2019

7 November 2019

8 December 2020

21 January 2024

8 references

25 April 2019

17 September 2019

19 September 2019

2 October 2019

7 November 2019

8 December 2020

21 January 2024

13

1 reference

page(s)

271-5

1 reference

issue

4

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

start time

20 March 2012

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 4.0 International

1 reference

https://scigraph.springernature.com/pub.10.1007/s10194-012-0428-7

Europe PubMed Central

21 January 2024

0 references

0 references

cites work

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Origin of pain in migraine: evidence for peripheral sensitisation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

What do patients with migraine want from acute migraine treatment?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

28 September 2017

Serotonin and migraine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Coronary side-effect potential of current and prospective antimigraine drugs

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3356470

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10194-012-0428-7

Evidence for a vascular factor in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10194-012-0428-7

Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10194-012-0428-7

21 January 2018

Neurobiology of migraine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22430431

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE

1 reference

https://api.crossref.org/works/10.1007%2FS10194-012-0428-7